Clinical trials: Acute Migraine
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
- Trial name
- NCT01445067
- Testing
- BMS-927711 (CGRP Antagonist)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Migraine Disorders, Migraine
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of…
- Trial name
- NCT00240630
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 50 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Migraine
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute…
- Trial name
- NCT00567086
- Testing
- TEZAMPANEL
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- TorreyPines Therapeutics
Migraine
Initiating Early Control of Migraine Pain and Associated Symptoms
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- INTERCEPT (NCT04163185)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan)
- Where
- 41 sites in United States
- Volunteers
- 302 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine, With or Without Aura
Safety and Efficacy in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03237845
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- Pfizer
Migraine, Acute Treatment of Migraine
Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment
Among US veterans, migraine is a prevalent and disabling neurological disorder, creating a clinical need for effective treatment options.
- Trial name
- NCT07336420
- Testing
- Nerivio REN device
- Where
- United States
- Volunteers
- 466 people
- Sponsor
- Theranica
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Acute Migraine
DFN-02 Open Label Safety Study in Patients With Acute Migraine
A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines
- Trial name
- NCT02279082
- Testing
- DFN-02
- Where
- 24 sites in United States
- Volunteers
- 167 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine With or Without Aura
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.
- Trial name
- NCT01986270
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg, Sumatriptan 25 mg
- Volunteers
- 1,141 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the…
- Trial name
- NCT01657370
- Testing
- MK-1602, Rescue medication
- Volunteers
- 195 people
- Sponsor
- Allergan
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
Migraine
Acute Treatment of Migraine Using the CEFALY Device
The purpose of this study is to investigate the efficacy of e-TNS with the Cefaly® device as an acute treatment for a migraine attack.
- Trial name
- NCT02411513
- Testing
- CEFALY
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cefaly Technology
Migraine With and Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
- Trial name
- NCT03185143
- Testing
- Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)
This is a randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care. .
- Trial name
- REAL (NCT03787238)
- Testing
- non-invasive vagus nerve stimulation
- Where
- 17 sites in Denmark, Germany and 3 more
- Sponsor
- ElectroCore INC
Acute Migraine
PBASE-system Acute Migraine Clinical Investigation
To evaluate the performance and safety of the PBASE-system when used in the treatment of acute migraine episodes of moderate to severe intensity.
- Trial name
- NCT01680029
- Testing
- PBASE-system 2.0
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Chordate Medical
Migraine Disorders
A Study of Gastric Delay in Migraine Patients (3207-003)
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
- Trial name
- NCT00548353
- Testing
- MK3207
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC